Lv21
150 积分 2025-09-24 加入
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
21天前
已完结
New Strategies for Multimodality Therapy in Treating Locally Advanced Cervix Cancer
21天前
已完结
Dostarlimab and niraparib in primary advanced ovarian cancer
21天前
已关闭
NTRK fusions in thyroid cancer: Pathology and clinical aspects
24天前
已完结
RET fusions in solid tumors
24天前
已完结
Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
24天前
已完结
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
24天前
已完结
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
24天前
已完结
The genetic prediction of risk for gynecologic cancers
24天前
已完结
Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women
24天前
已完结
皖公网安备34019202002308
